Imugene Improved HER-Vaxx
Edison | Jul 10, 2015 07:05AM ET
HER-Vaxx antibodies outperform Herceptin
Imugene Ltd (ASX:IMU) has developed a more potent formulation of its therapeutic cancer vaccine, HER-Vaxx, which will be tested in a Phase Ib/II trial in gastric (stomach) cancer in H215. HER-Vaxx could replicate or improve on the combination of two proven therapeutic antibodies, Herceptin and Perjeta (Roche), which significantly improves survival in breast cancer and may do so in gastric cancer. Imugene aims to gain a major pharma deal following Phase II data in the buoyant cancer immunotherapy area.
HER-Vaxx antibodies outperform Herceptin in vitro
Imugene recently highlighted previously published preclinical data showing that polyclonal antibodies produced following vaccination with HER-Vaxx were more potent than the marketed monoclonal antibody Herceptin at inhibiting the growth of breast cancer cells. Less than half the dose of HER-Vaxx-stimulated antibodies was required to inhibit cancer cell growth to the same degree as Herceptin.
Reformulated HER-Vaxx produces more antibodies
Imugene has developed a new formulation of HER-Vaxx that uses the vaccine carrier protein CRM197 together with an adjuvant, in place of the virosomes used in previous formulations. This new formulation stimulates faster immune responses and greater antibody production than the original vaccine used in Phase I trials. HER-Vaxx aims to stimulate a strong antibody response targeting normal HER-2 proteins, which are overexpressed in many breast and gastric cancer patients. The new formulation represents an important step towards this challenging goal and is the basis of a patent application that could extend IP protection by 6 years to 2036.
To Read the Entire Report Please Click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.